Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
HLS Therapeutics Inc.
Pharmaceutical Preparation ManufacturingCanada
Last verified 11 months agohlstherapeutics.com
HLS Therapeutics Inc., a prominent player in the pharmaceutical industry, is headquartered in Canada and operates extensively across North America. Founded in 2017, the company has quickly established itself as a leader in the development and commercialisation of innovative therapies, particularly in the areas of cardiovascular and central nervous system disorders.
HLS Therapeutics is renowned for its unique portfolio of products, including the well-regarded drug, Nabilone, which addresses chronic pain and nausea. The company’s commitment to enhancing patient outcomes through specialised treatments has positioned it favourably within the competitive landscape. With a focus on delivering high-quality, evidence-based solutions, HLS Therapeutics continues to achieve significant milestones, solidifying its reputation as a trusted name in healthcare.
26
DitchCarbon score
-16 vs industry average
HLS Therapeutics Inc.’s score of 26 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at HLS Therapeutics Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for HLS Therapeutics Inc. yet.
HLS Therapeutics Inc.'s reported carbon emissions
HLS Therapeutics Inc., headquartered in Canada, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that HLS Therapeutics may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, HLS Therapeutics may need to consider developing and communicating its climate commitments to align with broader environmental goals.
Assessing HLS Therapeutics Inc. as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for HLS Therapeutics Inc. and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
HLS Therapeutics Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for HLS Therapeutics Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
HLS Therapeutics Inc.11 months ago
26
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more